The Immuno Bill is a Reality! Guidance for the New “Medicare Part B-ID"
- Wednesday, November 2, 2022 - 2:00 pm to 3:00 pm EDT

Speakers:
- Matthew Cooper, MD, FAST • Director, Kidney and Pancreas Transplantation, MedStar Georgetown Transplant Institute, Washington, DC
- Nancy Edgington, LCSW III, CCTSW • Lead Kidney Transplant Social Worker, Yale New Haven Hospital, New Haven, CT
- Jennifer McDermott, PharmD, BCTXP, BCPS • Clinical Pharmacy Specialist, Solid Organ Transplant, Spectrum Health, Grand Rapids, MI

Moderator:
- Lisa Potter, PharmD, BCTXP, FCCP, FAST • Clinical Coordinator, Organ Transplant, University of Chicago Medicine, Chicago, IL

This topic was suggested by the AST Education Committee for inclusion in the 2022-2023 T3 webinar series. The Committee would like to thank the leadership of AST's Transplant Pharmacy Community of Practice (TxPharm COP) for their feedback on session speakers.

"Transplant Stewardship - Evidenced-Based Cost Containment Strategies in Solid Organ Transplantation"
- Wednesday, May 18, 2022 - 2:00 pm to 3:00 pm EST

Presenters:
- Margaret R. Jorgenson, PharmD, BCTXP • Clinical Pharmacist, University of Wisconsin Hospital and Clinics, Madison, WI
- Mary Moss Chandran, PharmD, BCTXP, BCPS, CPP, FAST • Clinical Pharmacist Practitioner, Solid Organ Transplant, UNC Hospitals and Clinics, Chapel Hill, NC

Moderator:
- Rita R. Alloway, PharmD, FCCP • Research Professor of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH

AST would like to thank the Transplant Pharmacy Community of Practice (TxPharm COP) for recommending this topic to include as part of the T3 webinar series.

Recorded live on Thursday, October 1, 2020 • Hosted jointly by the TxPharm & Pediatric Communities of Practice

"Three‐year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal."
(Am J Transplant . 2020 May 14. doi: 10.1111/ajt.16005.)

In this article:
CRADLE was a 36‐month multicenter study in pediatric (1-to-18 years) kidney transplant recipients randomized at 4 to 6 weeks posttransplant to receive everolimus + reduced‐exposure tacrolimus (EVR + rTAC; n = 52) with corticosteroid withdrawal at 6‐month posttransplant or continue mycophenolate mofetil + standard‐exposure TAC (MMF + sTAC; n = 54) with corticosteroids... The overall incidence of adverse events (AEs) and serious AEs was comparable between groups. Rejection was the leading AE for study drug discontinuation in the EVR + rTAC group. In conclusion, though AE‐related study drug discontinuation was higher, an EVR + rTAC regimen represents an alternative treatment option that enables withdrawal of steroids as well as reduction of CNIs for pediatric kidney transplant recipients. (ClinicalTrials.gov: NCT01544491)

Speakers:
Robert Ettenger, MD • David Geffen School of Medicine at UCLA, Los Angeles, CA
Nicole Hayde, MD, MS • Albert Einstein College of Medicine, New York, NY

Moderator:
Justin Chen, PharmD • New York-Presbyterian Hospital, New York, NY